Ocular Therapeutix Inc (OCUL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) has a cash flow conversion efficiency ratio of -0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.99 Million) by net assets ($581.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ocular Therapeutix Inc net asset quality index to measure how much of total assets are equity-financed.
Ocular Therapeutix Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check OCUL cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Ocular Therapeutix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocular Therapeutix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Eastern Airlines Corporation Limited
F:CIAH
|
0.231x |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
0.075x |
|
Intralot S.A. Integrated Lottery Systems and Services
AT:INLOT
|
0.306x |
|
BOTH Engineering Technology Co. Ltd. A
SHG:601133
|
N/A |
|
Blackstone Digital Infrastructure Trust Inc.
NYSE:BXDC
|
N/A |
|
BWP Trust
AU:BWP
|
0.020x |
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
0.041x |
|
Kajaria Ceramics Limited
NSE:KAJARIACER
|
0.074x |
Annual Cash Flow Conversion Efficiency for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ocular Therapeutix Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Ocular Therapeutix Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $654.31 Million | $-204.88 Million | -0.313x | +26.68% |
| 2024-12-31 | $315.34 Million | $-134.68 Million | -0.427x | +44.58% |
| 2023-12-31 | $91.13 Million | $-70.23 Million | -0.771x | +54.25% |
| 2022-12-31 | $35.38 Million | $-59.60 Million | -1.685x | -126.17% |
| 2021-12-31 | $88.00 Million | $-65.55 Million | -0.745x | -5.84% |
| 2020-12-31 | $76.09 Million | $-53.55 Million | -0.704x | -103.29% |
| 2019-12-31 | $-3.63 Million | $-77.58 Million | 21.371x | +1657.47% |
| 2018-12-31 | $35.88 Million | $-49.23 Million | -1.372x | +28.92% |
| 2017-12-31 | $26.15 Million | $-50.47 Million | -1.930x | -195.27% |
| 2016-12-31 | $52.01 Million | $-34.00 Million | -0.654x | -73.58% |
| 2015-12-31 | $89.59 Million | $-33.74 Million | -0.377x | -7.86% |
| 2014-12-31 | $58.70 Million | $-20.50 Million | -0.349x | -264.23% |
| 2013-12-31 | $-59.47 Million | $-12.64 Million | 0.213x | -21.25% |
| 2012-12-31 | $-46.61 Million | $-12.59 Million | 0.270x | -- |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more